THE PROCESS FOR THE EXPRESSION AND PRODUCTION OF THE RECOMBINANT GROWTH FACTOR PROTEIN (BEGF) DERIVED FROM BEAN 58058 VIRUS (BEV)

Abstract: The present invention describes recombinant growth factor (BEGF) protein isolated from the virus BeAn58058, its corresponding encoding recombinant DNA molecule and the process of production of the recombinant BEGF protein produced through genetic engineering techniques, to be used in human or veterinarian clinical or in research.

Description: THE PROCESS FOR THE EXPRESSION AND PRODUCTION OF THE RECOMBINANT GROWTH FACTOR PROTEIN (BEGF) DERIVED FROM BEAN 58058 VIRUS (BEV). TECHNICAL FIELD OF THE INVENTION The present invention refers to the general field of the technology of the DNA recombinant proteins, for the production of the recombinant growth factor (BEGF) of the virus BEAN 58058 , to be used in human or veterinarian clinical or in research. BACKGROUND OF THE INVENTION The growth is a primary, characteristic and fundamental process to any alive organism. Although it is usually associated to the initial stages of the life, the growth is present as a normal property through the adult life. This characteristic is showed mainly in the regenerative activities and in the process of programmed recycling of certain cellular types (James, R. & Bradshaw, R. A., Ann. Rev. Biochem. 53: 259-292, 1984). Several factors contribute to stimulating and controlling the growth . Among these factors are the hormones, neural growth factor, contact to proximal homologous or heterologous cells, interaction with extracelular structures (extracelular matrix), and others. Among the several agents involved in the process of growth regulation a group of proteins became particularly prominent in the last years, being recognized initially as hormones. However, the more careful analysis of these factors demonstrated that they possessed own characteristics and they became to be studied in a group that was called polypeptide growth factors or simply PGFs. Several characteristics differentiated these proteins from the hormones. Among them the fact that they are eminently protein molecules. PGFs are transported until the cell through tecidual diffusion, following an autocrine and paracrine secretion model. Contrarily the hormones present an endocrine secretion model, where the molecules are stocked in vesicles and released in the blood stream (James, R. & Bradshaw, R. A., Ann. Rev. Biochem. 53: 259-292, 1984). The first PGF isolated was the nervous growth factor (NGF) that acts stimulating the division and differentiation of sympathic nerves during the development of vertebrates. Other important member of the family of PGFs was discovered, soon after, in consequence of the study of the activity of NGF in mice. This new element was denominated epidermal growth factor (EGF) and it was detected by the stimuli of the growth of epidermal and epithelial cells. Several other growth factors were described, among them are the growth factors similar to the insulin (IGF I and II), Interleucin II (or growth factor of T cells), growth factor derived from plaqueta (PDGF), transforming growth factor (TGF) eritropoeitin, and others (James, R. & Bradshaw, R. A., Ann. Rev. Biochem. 53: 259-292, 1984; Carpenter, G., Ann. Rev. Biochem. 56: 881-914, 1987; Hillman, R.S. 1990. Hematopoietic agents: Growth factors, minerals and vitamins, in: Gilman, A. G. ;Rall, T. W. ;Niens, A. S. & Taylor, P. (ed.) The pharmacological basis of therapy. 8th edition. Louis Sanford, NY, USES., cap. 14, p. 277-1310, 1990). This superfamily of proteins includes elements structurally similar but with different physiologic functions. The main characteristic is that all these factors possess mitogenic and intrinsic regulatory activities, coordinating the cellular growth. In fact, each PGF possesses specific receptors, located in the plasmatic membrane of sensitive cells (James, R. & Bradshaw, R. A., Ann. Rev. Biochem. 53: 259-292, 1984). However these concepts are being modified, once today it is known that the receptors of EGF, for example, are present in a wide variety of cellular types, in different tissues. Besides, it is known that the receptors of EGF are responsible for the biological activity of at least two other growth factors similar to EGF: the transforming growth factor (TGF - α) and the growth factor of the vaccinia virus (VGF). The last is a molecule encoded in the genome of the vaccinia virus. Its function is probably associated to the mitotic proliferation of infected and non-infected cells. VGF is responsible for the proliferative activity of the cells through its binding to the receptors in these cells. This phenomenon, well known as molecular mimetism, would create favorable conditions for viral multiplication (Buller, R.M. & Palumbo, G.J., Microbiol. Rev., 55:80-122, 1991 ; Alamo, A. & Smith, GL, Immune. Today, 16: 474-478, 1995). The precursor polypeptides of EGF and TGF - α present peptide signal and transmembrane amino acid sequences, suggesting that these factors are located at the citoplasmatic membrane before they are ived originating mature molecules. In the same way, the precursor of the VGF protein presents hydrophobic amino acid in the amino and carboxy terminal that would work as peptide signal and transmembrane sequences (Stroobant,P. et al., Cell, .42: 383-393, 1985). VGF, EGF and TGF - α present groups of residues, mainly cysteins, highly conserved in the mature proteins. These residues, located in homologous sites in these growth factors, are responsible for the formation of three disulfide bridges, which are responsible for the tertiary structure of the molecules and, consequently, for its similar biological actions (Twardzik, D.R. et al, Proc. Natl. Acad. Sci. It USES, 82: 5300-5304, 1985). The growth factor of the virus BeAn 58058 (BEGF) presents amino acids sequences very similar to the sequence of VGF. There are modifications in the amino acid 17 and 78 in relation to the sequence of VGF. These modifications are changes of a leucin to a serin and an asparagin to lysine, respectively, in the polypeptide sequence of BEGF. During the decade of 80, the physiologic role of PGFs became questioned, once many of these factors became related with processes of cellular transformation and tumor development. PGFs that were initially related to the cellular transformation are EGF, PDGF and mainly the group of TGFs. Nevertheless, later authors began to evaluate the hypothesis of the therapeutic use of PGFs essentially based on its mitogenic properties. The possibility of the therapeutic use of these factors was tested firstly and used in the treatment of hematological diseases, that is the case of the eritropoeitin and of GM-CSF. Such factors have also been used as adjuvant in the treatment of serious infections and in patients submitted to chemotherapy with immune-supressor drugs. The eritropoietin is related to the eritropoiese and, in its absence, the patient presents serious anemia. The clinical use of GM- CSF has been tested with success in patients with neutropenia posterior to neoplasia , congenital neutropenia, aplasic anemia, mielodisplasias and AIDS. GM-CSF acts increasing the granulocyte and macrophages proliferation (Hillman, R.S. 1990. Hematopoietic agents: Growth factors, minerals and vitamins, in: Gilman, A. G. ;Rall, T. W. ;Niens, A. S. & Taylor, P. (ed.) The pharmacological basis of therapy. 8th edition. Louis Sanford, NY, USES., cap. 14, p. 277-1310, 1990). The therapeutic use of another PGFs is still very restricted and its use is still limited to the experimental field. However, the study of growth factors such EGF, PDGF, IGFs and TGFs open perspectives for the treatment of several illnesses, whose cure depends on tissue regeneration. In fact, Matsuda, N et al. (J. Periodontol. 63:515-525, 1992), tested with efficiency the action of several PGFs (EGF, PDGF, IGF-I and TGF -α) in the proliferation of mouse periodontal fibroblasts. Besides, an important increase in the synthesis of collagen of these cells was observed. These data evidence the possibility of the use of such factors in the treatment of periodontal diseases. The topical administration of EGF in small wounds caused by burns or incisions accelerates the epidermal regeneration through the stimulation of the keratinocytes, phenomenon necessary for the cicatrization process. In the same way, the topical administration of TGF - α and VGF accelerated the regeneration of wounds caused by burns of second degree. Besides, the treatment with TGF -α and VGF was shown to bemore efficient than the treatment with EGF, mainly when comparing the used amount ((Schultz et a/.Science, 235: 350-352, 1987.) These researches illustrate the clinical potential of the several well- known growth factors and they reflect the optimistic perspectives of the use of PGFs in another pathological processes that need inductors of cellular proliferation and regulatory elements of the growth. It is an object of the present invention to describe the recombinant BeAn 58058 growth factor (BEGF) protein isolated from virus BeAn58058, their corresponding encoding recombinant DNA molecule and the process of production of the recombinant BEGF protein produced through techniques of genetic engineering, to be used in human or veterinarian clinical or in research. BRIEF DESCRIPTION OF THE DRAWINGS These and other objects, features and many attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings wherein: BEFG protein. Figure 1 :The vector used for the expression of the recombinant BEGF protein Figure 2:Amino acid sequence of the recombinant BEGF protein Figure 3 Hydrophilicity of the recombinant BEGF protein Figure 4 - Detection and selection of the bacterial clones that produced the recombinant BEGF. Selected bacterial samples (£. coli, strain M15) were grown in LB medium until the D. O. e∞ of 0.7. The samples were then treated with IPTG, centrifuged and and prepared to PAGE analysis in a 15% polyacrilamida gel. Lane 1 :Mid range molecular weight marker (Promega, USA). Lanes 2, 4, 6, 8, 10 and 12: clones A10.1 , A70.1 , F70.1 , J70.1 and R.2, respectively, after induction with IPTG. Lanes 3, 5, 7, 9, 11 and 13: same clones without induction with IPTG. The arrow indicates a band that migrates at expected region for the recombinant BEGF. Figure 5 shows the purification of the recombinant BEGF through nickel chelate column. The selected clone (R.2) was grown in LB medium, induced with IPTG and pelleted trough centrifugation. The bacterial sediment was disrupted and loaded into the column. After that the column was washed with urea 8M pH 8.0 buffer. Protein fractions eluted in pHs of 6.5 to 4.5 were resolved in a 15% SDS-PAGE. Lane 1 : fraction eluted with guanidine 6M pH8.0. Lane 2: Fraction eluted with urea 8M pH 8.0. Lane 3: "A" fraction eluted with urea 8M pH 6.5. Lane 4: " B" fraction eluted with urea 8M pH 6.5. Lane 5: " A " fraction eluted wit ureaδM pH6.0. Lane 6: " B" fraction eluted with urea 8M pH 6.0. Lane 7: " C" fraction eluted with urea 8M pH 6.0. Lane 8: " D" fraction eluted with urea 8M pH 6.0. Lane 9: " A" fraction eluted with urea pH 5.5. Lane 10: "A" fraction eluted with urea 8M pH5.0. Lane 11 : Mid-range molecular size marker (Promega-USA). The arrow indicates a band that migrates at expected region for the recombinant BEGF. Figure 6 shows the c-fos mRNA accumulation in A431 cells. A431 cells were grown in MEM supplemented with 5% bovine fetal serum. After growth, the medium was discarded and cells were treated with several substances. After 30 minutes treatment cells were harvested and total RNA was extracted and resolved in agarose gel (A). The RNA was transferred to nylon membranes and hybridized with labeled c-fos gene probe. The filter was washed and exposed to X-ray films (B). The same filter was also probed with labeled 18S RNA (C). Cells were treated as follow: lane 1 : untreated cells; lane 2: cells treated with MEM supplemented with 20% bovine fetal serum; lane 3: cells treated with 8M pH6.0 urea buffer; lane 4: cells treated with "A" fraction eluted with urea 8M pH 6.0 (see figure 5, lane 5); lane 5: cells treated with protein loading buffer; lane 6: cells treated with non-induced bacterial extract diluted in protein loading buffer; lane 7: cells treated with IPTG induced bacterial extract diluted in protein loading buffer. DETAILED DESCRIPTION OF THE INVENTION The methodology used for the production of the recombinant BEGF protein consists of the cloning and expression, in microorganisms, of the DNA corresponding to the gene that codes the protein BEGF of the virus BeAn 58058 using the methodology of the genetic engineering. In order to better understand this invention the following examples, for illustrative purposes only, are described. The examples illustrate the present invention and are not intended to limit it in spirit or scope. The process can be understood better through the following description in consonance with the examples: EXAMPLE 1 DNA amplification(l) The amplification of the fragment corresponding to the BEGF starting from the DNA of the virus BeAn 58058 or starting from the vector that contains the cloned fragment of the gene was carried out using specific oligonucleotides 5'CGCAGGATCCATATCAGATCATTCGCCGAT3 ' and 5'CCAGAAGCTTTGGCACAACCATATC3 '. Those oligonucleotides was drawn to amplify the DNA region that encodes the corresponding fragment of the BEGF protein and contains the sites for the restriction enzymes BamH 1 and Hind III, in the polymerase chain reaction (PCR). The reaction was made with Taq polymerase buffer (500 mM KCI, 100 mM Tris-HCI pH 9.0-9.5, 1.5-2.5 mM MgCI 2 and 1-2% triton X-100), 0.1-1 U of Taq polymerase (Promega ,E.U.A., Cat. no. M186A), 0.5-1.5 mM MgCI 2 , 20-50 mM of each nucleotide (dATP,dCTP,dGTP,dTTP) 10-30 pmoles of each primer, and 0.01a 0.1 ng cDNA and H 2 O q.s.p. 50-100 μl. The reaction was seen in 1-2 cycles at 94-96°C/1-2 min; 53 to 55°C/1 -2 min.; 70-72X /1 - 2 min; 30 cycles at 94-96°C/1 to 2 min; 36 -38°C/1-2min; 70- 72°C/1-2 min and more 1 cycle to 94-96°C/1-2 min; 36 -38X/1 to 2 min; 70-72°C/10-15 min. The fractionation of the DNA was accomplished by eletrophoresis in 1.5-2.0% agarose gel. The purification of the amplified DNA was made by cutting out the band of the gel. The band was diluted in 2-3 times the volume of Nal solution (Nal 8M + 0.022 M DTT) and sodium phosphate buffer (1M pH 6.0-6.5) and incubated for 5-10 min. to 50-56X. Glass beads were added to the suspension, mixed , incubated 1-5 min. at room temperature and centrifuged 10-30 seconds . The spheres were washed with ethanol buffer(75% of ethanol, 0.01 M Tris-HCI, pH 7.0-7.6, 0.01 M EDTA, pH 8.0-8.5). The DNA was eluted from the glass spheres with buffer(Tris pH 7.0-7.4 10 mM, 1-3 mM EDTA) at 50-56° C for 1-5 min. EXAMPLE 2 Cloning (2) The digestion of the DNA it was firstly treated with enzyme Hind III in a reaction with 10-20 U of Hind III (Biolabs, England), 3-5 μl buffer (Promega,EUA) and H 2 O qsp 30-50 μl. The reactions were incubated at 37oC for 2-4 h. After this time 10-20 U of Bam HI (Biolabs, England), 5-10 μl of react III (BRL, USA), H 2 O dd qsp 50-1 OOμl were added to the reaction and it was incubated at 37°C for 2-4 h. For cloning of the DNA fragment in the plasmid PDS-56 (Figure 1 ), the digestion of the vector was accomplished with the restriction enzymes Hind III and Bam HI in a reaction that contents vector, 10-20 U of enzyme Hind lll(Promega, USA), 2-5 μl (buffer I B (Promega.E.U.A), H 2 O qsp 20-50μl, with incubation at 37°C for 2-4 h. Later 10-20 U of the enzyme Bam HI (Promega, USA), 5- 10 μl of react III (BRL, E.U.A), H2O qsp 50-100μl were added to the reaction and incubated at 37°C for 2-4 h. The product of this digestion was analyzed by eletrophoresis in a 1 % TAE-agarose gel he band corresponding to the digested plasmid was cutted out of the gel and transferred to a Eppendorf tube (1 ,5 ml) and purified. In the ligation reaction 20-50 ng of the insert DNA fragment was added to 5-15 ηg of the vector DNA, 0,5-2,0 U of T4 ligase (Promega, USA), ATP 5 mM (Promega, E.U.A.), ligation buffer(Promega,E.U.A), H 2 O dd qsp 15μl, with incubation at 14-16°C (BOD, FANEN, Brazil) for 12-18 h. EXAMPLE 3 Transformation (3) The bacterial transformation was done with Escherichia coli . The volume of the ligation reaction was completed to 40-60μl with buffer(Tris 10 mM pH 7.2-7.4, EDTA 1 mM) and added to 100 μl of suspension of competent bacteria. The tubes were slightly rotated and immediately incubated on ice bath 20-40 min , submitted to a thermal shock at 40-42°C for 1-3 min. and again on ice bath for 20-40 seconds. LB medium (Bacto triptona 1 % p/v, extract of yeast 0.5% p/v, NaCI 171 mM) without antibiotic was added at double volume and incubated at 37°C for 1-2h. The bacteria were pelleted, homogenized in LB and inoculated in Petri plates with LB agar (agar 1.5% p/v, yeast extract 0.5% p/v, triptone 0.1 % p/v, NaCI 0.5% p/v pH 7.2-7.5) with 50-200 μg/ml ampicylin and 20-100 μg/ml kanamicyne. The plates were incubated at 37°C for 15-24 h. For the selection of the positive clones they were grown in LB with 50-200 μg/ml ampicilin and 20-100 μg/ml kanamicyne at 37°C under agitation for 15-20 h. After incubation a PCR using specific primers of the vector (for amplification of the area corresponding to insert) being the primer (sense) 5'-TTCATTAAAGAGGAGAAATT-3 , and primer(anti-sense) 5'- CTATCAACAGGAGTCCAAGC-3' The reaction was made with Taq. polymerase bufferlO X (KCI 500 mM, Tris-HCI 100 mM pH 9.0-9.5, MgCI 2 15-25 mM and triton X-100 1-2%), 0.5-1.0 U of Taq polymerase (Promega, USA), 0.5-1.5 mM MgCI 2, 20-50 mM of each nucleotide (dATP, dCTP, dGTP, dTTP), 10-30 pmoles of each primer, 0.5-1 μl of bacterial suspension and H 2 Odd sterile qsp 20-40μl. The reaction was processed with 1-3 cycles of 94-96°C/5min., 50-55°C/1-2 min., 70-72°C/1-2 min.; 30 cycles of 94-96°C/30-45 seg., 45-50°C/30-45 seg., 70-72°C/30-45 seg. and 1 cycle of 94-96°C/1-2 min., 45-50°C/1-2 min., 70-72°C/10-15min. The product of this reaction was fractionated through 1-2%.agarose gel eletrophoresis. EXAMPLE 4 Sequencing (4) The positive clones were sequenced to confirm the sequence of Figure 2 and presents the hydrofobicity profile as showed in Figure 3. EXAMPLE 5 Protein production (5) The positive clones were used for the production of the protein and they were grown in LB medium with 50-200 μg/ml ampiciline and 50-200 of Kanamicyne μg/ml and incubated at 37°C under agitation until the optical density (OD 600 nm) of 0.5-0.7. Then, for the induction of the protein, IPTG(lsopropyl-(-D-thiogalacoside) to 0.2-0.4 M was added and incubated for 3-5 h. The bacteria's were centrifuged and the supernatant was discarded and the pellet homogenized in buffer A(Guanidine-HCI 5-6 M, sodium phosphate 0.1-0.2 M, Tris 0.01-0.02 M pH 7.8-8.0) with agitation for 1-2 h. A polycrylamida gel shows the expression in the bacteria. (Figure 4) EXAMPLE 6 Protein purification (6) After it was centrifuged the supernatant was applied to a column with Ni- NTA (nickel chelate) resin. For the purification of the protein the column

Claims: was washed sequentially with buffer A, buffer B (Urea 7-8 M, phosphate of sodium 0,1-0,2 M, Tris 0.01-0.02 M pH 7.8-8.0) and with buffer C (Urea 7-8 M, phosphate of sodium 0.1-0.2 M, Tris 0.01-0.02 M pH 7.0-7.2). The protein was eluted with buffer D (Urea 7-8 M, sodium phosphate 0.1-0.2 M, Tris 0.01-0.02 M pH 5.0-5.2) and sequentially with Urea 7-8 M, phosphate of sodium 0.1-0.2 M, Tris 0.01-0.02 M pH 40-4.2; fractions were collected and 50μl of each fraction was diluted v/v in sample buffer, heated for 10 min. and submitted to electrophoresis in polyacrylamida gel (SDS-PAGE). The gel was analyzed for the presence of the fraction that just contained the band corresponding to the purified recombinant BEGF (Figure 5) and the biological activity was measured in A431 cells (Figure 6) While the present invention has been described in connection with examples, it will be understood that modifications and variations apparent to those ordinary skill in the art are within the scope of the present invention. WHAT IS CLAIMED IS: 1. Process for production of the human recombinant growth factor protein BEGF in comprising the following steps: (1 )DNA amplification (2)cloning (3) transformation (4)Sequencing (5) Protein production (6) Protein purification 2The process according to claim 1 , wherein the stages: (1 ), (2), (3), (4) can be optional. 3. Process for production of the recombinant growth factor protein BEGF according to claim 1 , wherein the amplification of DNA (1 ) is done using BEAN58058 virus or any other that posses the same sequence. 4. Process for production of the recombinant growth factor protein BEGF according to claim 1 , wherein the cloning (2) of the DNA is done in plasmid pDS56 or any other expression vector. 5. Process for production of the recombinant growth factor protein BEGF according to claim 1 , wherein the transformation of the competent bacteria (3) is done with bacteria Escherichia coli or any other microorganism 6. Process for production of the recombinant growth factor protein BEGF according to claim 1 , wherein the protein production (5) is done in Escherichia coli or any other microorganism 7. Process for production of the recombinant growth factor protein BEGF according to claim 1 , wherein the fact that the purification of the protein (6) is done in a column of nickel chelate or any other method that allows the purification of the protein. 8. Recombinant growth factor protein BEGF manufactured through the demanded process of 1-6, wherein the structure presents the following aminoacids: MetllelleArgSerPheAlaAspSerGly.AsnAlalleGluThrThrSerProGlulle. ThrAsnAlaThrThrAsplleProAlalle.ArgLeuCysGlyProGluGlyAspGlyTyr CysLeuHisGlyAspCyslleHisAlaArg.AsplleAspGlyMetTyrCysArgCysSer HisGlyTyrThrGlylleArgCysGlnHis.ValValLeuValAspTyrGlnArgSerGlu LysProAsnThrThrThrSerTyrllePro.SerProGlylleMetLeuValLeuValGly HellellelleThrCysCysLeuLeuSer.ValTyrArgPheThrArgArgThrLysLeu ProlleGlnAspMet ValValPro

Inventors: GEESSIEN KROON ERNA, GUIMARAES DA FONSECA FLAVIO, PEREGRINO FERREIRA PAULO CESAR, GEESSIEN KROON, ERNA, GUIMARAES DA FONSECA, FLAVIO, PEREGRINO FERREIRA, PAULO, CESAR
Applicants: GEESSIEN KROON ERNA, GUIMARAES DA FONSECA FLAVIO, PEREGRINO FERREIRA PAULO CESAR, UNIV MINAS GERAIS, GEESSIEN KROON, ERNA, GUIMARAES DA FONSECA, FLAVIO, PEREGRINO FERREIRA, PAULO, CESAR, UNIVERSIDADE FEDERAL DE MINAS GERAIS
Application year: 1997
Main classification: C12N15
IPC codes: C07K14, C12N15